FDA Approves Abraxane for Pancreatic Cancer

ABRAXANE® (generic name: nab-paclitaxel) was approved by the FDA as first-line therapy for the metastatic adenocarcinoma of the pancreas when used in combination with gemcitabine. The approval of ABRAXANE is a major development in pancreatic cancer care and is expected to replace gemcitabine alone as a new standard of care for pancreatic cancer. 

Emerging Target, “Cell Metabolism”: From Boondocks to Harvard Square, Boston

The emergence of “cancer energy metabolism” as one of the promising targets, is affirmed by the two significant Pharma deals this year: